Takeda Liable In IBS Drug Pay-For-Delay Trial
By Carolyn Muyskens · May 18, 2026, 3:13 PM EDT
A federal jury in Boston on Monday found Takeda Pharmaceuticals conspired with a generic-drug maker to delay the launch of a generic version of Takeda's anti-constipation drug, awarding purchasers $885 million, a...
To view the full article, register now.